CD33 and breast carcinoma: By contrast, several kinds of tumor-infiltrating immune/inflammatory cells, such as Foxp3+ Tregs, CD33+ myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), were correlated with clinicopathological features, worse breast cancer-specific survival, and shorter disease-free interval [30,31].